Summary

The epigenetics market is expected to reach USD 3.92 billion in 2031 from USD 2.22 billion in 2026, at a CAGR of 12.0% during the forecast period. The market is expected to grow steadily during the forecast period, driven by increasing use of epigenetic analysis in oncology research, precision medicine, drug discovery, biomarker validation, and translational studies. Technologies such as next-generation sequencing, PCR & qPCR, mass spectrometry, sonication-based chromatin preparation, and methylation arrays enable the analysis of DNA methylation, histone modifications, chromatin accessibility, non-coding RNAs, and chromatin remodeling. These tools support applications across cancer diagnostics, therapeutic target identification, disease classification, treatment response monitoring, developmental biology, immunology, neuroscience, and metabolic disease research. The growing use of liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration, and AI-enabled data interpretation is further strengthening adoption across pharmaceutical, biotechnology, academic, clinical, and CRO settings. In addition, demand for standardized kits, high-quality antibodies, sequencing reagents, enzymes, automated sample preparation solutions, and bioinformatics platforms is improving workflow reproducibility and data reliability. However, market growth continues to be challenged by high sequencing and analysis costs, complex data interpretation, variability in antibody performance, and difficulties in standardizing epigenetic workflows for broader clinical use.

“DNA methylation segment is expected to grow at the highest CAGR during the forecast period”
The DNA methylation segment is projected to grow at the highest CAGR in the epigenetics market due to its increasing use in cancer detection, biomarker discovery, disease classification, and treatment response monitoring. DNA methylation assays are widely used to study promoter methylation, gene silencing, epigenetic aging, tumor profiling, and liquid biopsy-based diagnostics. The growing adoption of bisulfite sequencing, methylation-specific PCR, methylation arrays, and NGS-based methylation profiling is strengthening demand across pharmaceutical research, clinical laboratories, and translational studies.

“Next-generation sequencing segment holds the largest share of the market”
The next-generation sequencing segment accounts for the largest share of the epigenetics market, driven by its ability to generate high-throughput, genome-wide insights into epigenetic regulation. NGS is widely used in DNA methylation profiling, ChIP-seq, ATAC-seq, chromatin accessibility studies, and single-cell epigenomics. Its strong adoption across oncology research, biomarker discovery, drug development, and precision medicine supports its leading position. The increasing need for deeper epigenomic coverage, scalable analysis, and integration with multi-omics workflows continues to strengthen demand for NGS-based epigenetics solutions.
“The US is expected to grow at the highest CAGR during the forecast period”
The US is expected to grow at the highest CAGR in the epigenetics market due to its strong presence of sequencing, molecular biology, diagnostics, and bioinformatics companies, advanced research infrastructure, and high adoption of epigenomic technologies across research and clinical settings. Rising use of epigenetics in oncology, precision medicine, drug discovery, liquid biopsy development, and biomarker validation is driving market growth. Technologies such as next-generation sequencing, PCR & qPCR, methylation arrays, ChIP-seq, ATAC-seq, and single-cell epigenomics are widely used across pharmaceutical companies, biotechnology firms, academic institutes, CROs, and clinical laboratories.
The primary interviews conducted for this report can be categorized as follows:

・By Respondent: Supply Side – 70% and Demand Side– 30%
・By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
・By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%
Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), Revvity (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), EpigenTek Group Inc. (US), EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), BPS Bioscience, Inc. (US), Abnova Corporation (Taiwan), Creative Diagnostics (US), Biomodal (UK), 10x Genomics (US), and Novogene Co., Ltd. (China) are some of the key companies offering epigenetics products and services.

Research Coverage
This research report categorizes the epigenetics market by offering (products and services), product [kits & reagents {antibodies, isolation/extraction kits & reagents, ChIP-sequencing kits & reagents, bisulfite conversion kits & reagents, whole-genome amplification kits & reagents, CUT&RUN/CUT&TAG kits & reagents, 5-hmC & 5-mC analysis kits & reagents, histones, and other kits & reagents}, enzymes {DNA polymerases, DNA ligases, Tn5 transposase, conversion enzymes [TET & APOBEC], protein-modifying enzymes, and other enzymes}, and instruments & accessories], service (DNA methylation profiling services, chromatin profiling services, chromatin accessibility profiling services, single-cell epigenomics services, multi-omics services, and other services), technology (next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies), method (DNA methylation, histone modifications, and other methods), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, population screening, and other applications), products market by end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), services market by end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, and contract research organizations), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the epigenetics market. This report also includes a competitive analysis of emerging startups in the epigenetics industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
・Analysis of key drivers (declining sequencing costs and time, growing emphasis on population screening programs, technological advancements in epigenetics research, rising demand for epigenetic drugs and epigenetic-based therapeutics), restraints (limited applications of epigenomic data in toxicology, data privacy concerns and security issues), opportunities (emerging applications of epigenetics, integration of multi-omics), and challenges (concerns regarding quality of antibodies, challenges associated with epigenetic editing) influencing the market growth
・Product Development/Innovation: Detailed insights into newly launched products and innovations in the epigenetics market
・Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market
・Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), and Revvity (US), among others, for the epigenetics market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.3 MARKET SCOPE 46
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 47
1.3.2 INCLUSIONS & EXCLUSIONS 48
1.3.3 YEARS CONSIDERED 49
1.3.4 CURRENCY CONSIDERED 49
1.4 STAKEHOLDERS 50
1.5 SUMMARY OF CHANGES 50
2 EXECUTIVE SUMMARY 51
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 51
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 53
2.3 DISRUPTIVE TRENDS IN EPIGENETICS MARKET 54
2.4 HIGH-GROWTH SEGMENTS 55
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 56
3 PREMIUM INSIGHTS 57
3.1 EPIGENETICS MARKET OVERVIEW 57
3.2 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD AND COUNTRY 58
3.3 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
3.4 EPIGENETICS MARKET SHARE, BY OFFERING, 2026 VS. 2031 59
4 MARKET OVERVIEW 60
4.1 INTRODUCTION 60
4.2 MARKET DYNAMICS 60
4.2.1 DRIVERS 61
4.2.1.1 Declining sequencing costs and time 61
4.2.1.2 Growing emphasis on population-scale screening initiatives 62
4.2.1.3 Technological advancements in epigenetics research 62
4.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics 62
4.2.2 RESTRAINTS 63
4.2.2.1 Limited applications of epigenomic data in toxicology 63
4.2.2.2 Data privacy concerns and security issues 63
4.2.3 OPPORTUNITIES 64
4.2.3.1 Emerging applications of epigenetics 64
4.2.3.2 Integration of multi-omics 64
4.2.4 CHALLENGES 64
4.2.4.1 Concerns regarding quality of antibodies 64
4.2.4.2 Challenges associated with epigenetic editing 65
4.3 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65
4.4 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 66
5 INDUSTRY TRENDS 67
5.1 PORTER’S FIVE FORCES ANALYSIS 67
5.1.1 BARGAINING POWER OF SUPPLIERS 68
5.1.2 BARGAINING POWER OF BUYERS 68
5.1.3 THREAT OF NEW ENTRANTS 69
5.1.4 THREAT OF SUBSTITUTES 69
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.2 MACROECONOMIC OUTLOOK 69
5.2.1 INTRODUCTION 69
5.2.2 GDP TRENDS AND FORECAST 70
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 70
5.2.4 TRENDS IN GLOBAL BIOTECH & PHARMA INDUSTRY 71
5.3 VALUE CHAIN ANALYSIS 71
5.4 ECOSYSTEM ANALYSIS 73
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 74
5.5 PRICING ANALYSIS 76
5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2023–2025 76
5.5.1.1 Average selling price trend, by instrument, 2023–2025 76
5.5.1.2 Average selling price trend, by kits & reagents, 2023–2025 77
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 77
5.6 TRADE ANALYSIS 78
5.6.1 IMPORT SCENARIO (HS CODE 9027.50) 79
5.6.2 EXPORT SCENARIO (HS CODE 9027.50) 80
5.6.3 IMPORT SCENARIO (HS CODE 3822.00) 81
5.6.4 EXPORT SCENARIO (HS CODE 3822.00) 82
5.7 KEY CONFERENCES & EVENTS, 2026–2027 83
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84
5.9 INVESTMENT & FUNDING SCENARIO 85
5.10 CASE STUDY ANALYSIS 86
5.10.1 CFDNA METHYLOME–FRAGMENTOME PROFILING STRENGTHENS MULTICANCER DETECTION 86
5.10.2 5-BASE NGS WORKFLOW ENABLES INTEGRATED METHYLATION AND
VARIANT PROFILING 86
5.10.3 LONG-READ SEQUENCING SCALES NATIVE EPIGENOME ANALYSIS
IN AGING RESEARCH 87
 
5.11 IMPACT OF 2025 US TARIFF ON EPIGENETICS MARKET 87
5.11.1 INTRODUCTION 87
5.11.2 KEY TARIFF RATES 87
5.11.3 PRICE IMPACT ANALYSIS 88
5.11.4 IMPACT ON COUNTRIES/REGIONS 89
5.11.4.1 US 89
5.11.4.2 Europe 89
5.11.4.3 Asia Pacific 90
5.11.5 IMPACT ON END-USE INDUSTRIES 90
5.11.5.1 Pharmaceutical and biotechnology companies 90
5.11.5.2 Contract research organizations 90
5.11.5.3 Academic and research institutes 91
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 92
6.1 INTRODUCTION 92
6.1.1 KEY TECHNOLOGIES 92
6.1.1.1 DNA methylation conversion technologies 92
6.1.1.2 Chromatin immunoprecipitation/ChIP 92
6.1.1.3 ATAC-based chromatin accessibility profiling 93
6.1.2 COMPLEMENTARY TECHNOLOGIES 93
6.1.2.1 Single-cell partitioning and epigenomic barcoding 93
6.1.2.2 AI/ML-based epigenomic interpretation 93
6.1.3 ADJACENT TECHNOLOGIES 94
6.1.3.1 CRISPR-based epigenome modulation 94
6.1.3.2 Spatial epigenomics 94
6.2 TECHNOLOGY ROADMAP 95
6.3 PATENT ANALYSIS 95
6.3.1 METHODOLOGY 95
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 95
6.3.3 LIST OF KEY PATENTS 97
6.4 FUTURE APPLICATIONS 97
6.5 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET 98
6.5.1 TOP USE CASES AND MARKET POTENTIAL 99
6.5.2 BEST PRACTICES IN AI-ENABLED EPIGENETICS WORKFLOWS 100
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET 100
6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS 101
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES 101
 
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 103
7.1 REGIONAL REGULATIONS AND COMPLIANCE 103
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
7.1.2 INDUSTRY STANDARDS 107
7.1.2.1 North America 107
7.1.2.2 Europe 107
7.1.2.3 Asia Pacific 108
7.1.2.4 Rest of the World 108
7.2 SUSTAINABILITY INITIATIVES 108
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 109
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS 109
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113
8.1 DECISION-MAKING PROCESS 113
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 113
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113
8.2.2 KEY BUYING CRITERIA 114
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 115
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 116
9 EPIGENETICS MARKET, BY OFFERING 117
9.1 INTRODUCTION 118
9.2 PRODUCTS 118
9.2.1 RISING ADOPTION OF WORKFLOW-READY EPIGENETICS
PRODUCTS TO PROPEL MARKET 118
9.3 SERVICES 121
9.3.1 RISING OUTSOURCING OF COMPLEX EPIGENOMIC WORKFLOWS
TO DRIVE MARKET 121
10 EPIGENETICS MARKET, BY PRODUCT 125
10.1 INTRODUCTION 126
10.2 KITS & REAGENTS 127
10.2.1 ANTIBODIES 131
10.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market 131
10.2.2 ISOLATION/EXTRACTION KITS & REAGENTS 134
10.2.2.1 Rising need for high-quality, automation-ready sample preparation to propel market 134
10.2.3 CHIP-SEQUENCING KITS & REAGENTS 138
10.2.3.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market 138
 
10.2.4 BISULFITE CONVERSION KITS & REAGENTS 141
10.2.4.1 Effective outcomes associated with bisulfite conversion to sustain growth 141
10.2.5 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS 145
10.2.5.1 Rising use of low-input and single-cell epigenomic workflows to stimulate growth 145
10.2.6 CUT&RUN/CUT&TAG KITS & REAGENTS 148
10.2.6.1 Rising adoption of low-input chromatin profiling workflows to stimulate growth 148
10.2.7 5-HMC & 5-MC ANALYSIS KITS & REAGENTS 152
10.2.7.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth 152
10.2.8 HISTONES 155
10.2.8.1 Rising importance of chromatin-associated proteins and histones in epigenetic research to propel growth 155
10.2.9 OTHER KITS & REAGENTS 159
10.3 ENZYMES 162
10.3.1 DNA POLYMERASES 165
10.3.1.1 Rising need for uracil-tolerant, low-bias DNA amplification to facilitate growth 165
10.3.2 DNA LIGASES 169
10.3.2.1 Rising need for efficient adapter ligation in low-input epigenomic library preparation to spur growth 169
10.3.3 TN5 TRANSPOSASE 172
10.3.3.1 Rising adoption of tagmentation-based chromatin profiling to facilitate growth 172
10.3.4 CONVERSION ENZYMES 176
10.3.4.1 Rising shift toward enzymatic DNA conversion for low-damage methylome profiling to spur growth 176
10.3.5 PROTEIN-MODIFYING ENZYMES 179
10.3.5.1 Rising focus on histone post-translational modification analysis to spur growth 179
10.3.6 OTHER ENZYMES 183
10.4 INSTRUMENTS & ACCESSORIES 186
10.4.1 RISING ADOPTION OF HIGH-THROUGHPUT, AUTOMATED, AND LONG-READ EPIGENOMIC PLATFORMS TO EXPEDITE GROWTH 186
11 EPIGENETICS MARKET, BY SERVICE 190
11.1 INTRODUCTION 191
11.2 DNA METHYLATION PROFILING SERVICES 191
11.2.1 OUTSOURCING OF COMPLEX METHYLATION WORKFLOWS AND ONCOLOGY BIOMARKER RESEARCH TO DRIVE MARKET 191
11.3 CHROMATIN PROFILING SERVICES 195
11.3.1 RISING OUTSOURCING OF LOW-INPUT AND MULTI-OMIC CHROMATIN MAPPING WORKFLOWS TO DRIVE MARKET 195
 
11.4 CHROMATIN ACCESSIBILITY PROFILING SERVICES 198
11.4.1 RISING USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET 198
11.5 SINGLE-CELL EPIGENOMICS SERVICES 202
11.5.1 RISING NEED FOR CELL-LEVEL REGULATORY INSIGHTS TO AID GROWTH 202
11.6 MULTI-OMICS SERVICES 205
11.6.1 RISING DEMAND FOR INTEGRATED EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC INTERPRETATION TO SUPPORT GROWTH 205
11.7 OTHER SERVICES 209
12 EPIGENETICS MARKET, BY TECHNOLOGY 213
12.1 INTRODUCTION 214
12.2 NEXT-GENERATION SEQUENCING 214
12.2.1 INCREASING LAUNCHES OF NGS PLATFORMS TO DRIVE GROWTH 214
12.3 PCR & QPCR 218
12.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET 218
12.4 MASS SPECTROMETRY 222
12.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET 222
12.5 SONICATION 225
12.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO DRIVE MARKET 225
12.6 OTHER TECHNOLOGIES 229
13 EPIGENETICS MARKET, BY METHOD 233
13.1 INTRODUCTION 234
13.2 DNA METHYLATION 234
13.2.1 RISING USE OF METHYLATION-BASED BIOMARKERS IN ONCOLOGY, LIQUID BIOPSY, AND PRECISION MEDICINE TO SPUR GROWTH 234
13.3 HISTONE MODIFICATION 238
13.3.1 EXPANDING USE OF HISTONE MODIFICATION PROFILING IN CHROMATIN BIOLOGY, DRUG DISCOVERY, AND MULTI-OMICS RESEARCH TO DRIVE MARKET 238
13.4 OTHER METHODS 242
14 EPIGENETICS MARKET, BY APPLICATION 245
14.1 INTRODUCTION 246
14.2 ONCOLOGY 246
14.2.1 RISING USE OF EPIGENETIC BIOMARKERS AND CHROMATIN-REGULATING DRUG TARGETS TO BOOST MARKET 246
14.3 METABOLIC DISEASES 252
14.3.1 INCREASING USE OF DNA METHYLATION BIOMARKERS TO ADVANCE METABOLIC DISEASE RISK PREDICTION AND THERAPEUTIC RESEARCH 252
 
14.4 IMMUNOLOGY 255
14.4.1 RISING USE OF EPIGENETIC IMMUNE PROFILING TO DRIVE MARKET 255
14.5 DEVELOPMENTAL BIOLOGY 259
14.5.1 INCREASED USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET 259
14.6 CARDIOVASCULAR DISEASES 262
14.6.1 RISING USE OF DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR RISK PREDICTION AND THERAPEUTIC TARGET DISCOVERY TO AID GROWTH 262
14.7 POPULATION SCREENING 266
14.7.1 INCREASING USE OF DNA METHYLATION BIOMARKERS FOR EXPOSURE-LINKED POPULATION RISK ASSESSMENT TO AID GROWTH 266
14.8 OTHER APPLICATIONS 269
15 EPIGENETIC PRODUCTS MARKET, BY END USER 273
15.1 INTRODUCTION 274
15.2 ACADEMIC & RESEARCH INSTITUTES 274
15.2.1 INCREASED IN-HOUSE ADOPTION OF ADVANCED EPIGENOMICS PRODUCTS ACROSS ACADEMIC DISCOVERY RESEARCH TO FAVOR GROWTH 274
15.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 278
15.3.1 RISING USE OF EPIGENETICS PRODUCTS IN DRUG DISCOVERY
TO PROPEL MARKET 278
15.4 HOSPITALS & CLINICS 281
15.4.1 RISING INTEGRATION OF METHYLATION-BASED MOLECULAR PROFILING IN HOSPITAL ONCOLOGY WORKFLOWS TO PROPEL MARKET 281
15.5 CONTRACT RESEARCH ORGANIZATIONS 285
15.5.1 INCREASING DEMAND FOR STANDARDIZED AND SCALABLE EPIGENOMIC WORKFLOWS TO DRIVE MARKET 285
16 EPIGENETICS SERVICES MARKET, BY END USER 289
16.1 INTRODUCTION 290
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 290
16.2.1 RISING USE OF OUTSOURCED EPIGENETIC BIOMARKER AND TARGET-VALIDATION SERVICES TO ACCELERATE DRUG DEVELOPMENT DECISIONS 290
16.3 ACADEMIC & RESEARCH INSTITUTES 294
16.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH 294
16.4 HOSPITALS & CLINICS 297
16.4.1 RISING USE OF OUTSOURCED METHYLATION PROFILING AND CLASSIFIER-BASED INTERPRETATION TO AID GROWTH 297
 
17 EPIGENETICS MARKET, BY REGION 301
17.1 INTRODUCTION 302
17.2 NORTH AMERICA 302
17.2.1 US 309
17.2.1.1 Strong pharmaceutical R&D intensity and advanced genomics infrastructure to drive market 309
17.2.2 CANADA 314
17.2.2.1 Presence of advanced clinical genomics infrastructure to support market growth 314
17.3 EUROPE 319
17.3.1 GERMANY 324
17.3.1.1 Established life sciences supply ecosystem to drive market 324
17.3.2 UK 328
17.3.2.1 Growing emphasis on precision medicine to propel market 328
17.3.3 FRANCE 333
17.3.3.1 Strong oncology research ecosystem to support market growth 333
17.3.4 ITALY 338
17.3.4.1 High incidence of cancer to drive market 338
17.3.5 SPAIN 342
17.3.5.1 Well-established network of research centers and universities to propel market 342
17.3.6 REST OF EUROPE 346
17.4 ASIA PACIFIC 351
17.4.1 CHINA 356
17.4.1.1 Advanced methylation detection and sequencing service capacity to accelerate growth 356
17.4.2 JAPAN 360
17.4.2.1 Increasing collaborations between research & academic organizations to favor growth 360
17.4.3 INDIA 365
17.4.3.1 Expanding genomics infrastructure to drive market 365
17.4.4 AUSTRALIA 369
17.4.4.1 Strong genomics infrastructure to propel market 369
17.4.5 SOUTH KOREA 373
17.4.5.1 Methylation profiling and AI-enabled epigenomic analysis to foster growth 373
17.4.6 REST OF ASIA PACIFIC 378
17.5 LATIN AMERICA 383
17.5.1 BRAZIL 387
17.5.1.1 Rising prevalence of chronic diseases to drive market 387
17.5.2 MEXICO 392
17.5.2.1 Growing adoption of cutting-edge technologies to drive market 392
17.5.3 REST OF LATIN AMERICA 396
17.6 MIDDLE EAST 401
17.6.1 GCC COUNTRIES 406
17.6.1.1 Saudi Arabia 410
17.6.1.1.1 Growing healthcare expenditure to propel market 410
17.6.1.2 UAE 415
17.6.1.2.1 National genomics programs and methylation-enabled sequencing to spur growth 415
17.6.1.3 Rest of GCC countries 419
17.6.2 REST OF MIDDLE EAST 424
17.7 AFRICA 429
17.7.1 POPULATION-SPECIFIC BIOMARKER DISCOVERY AND DISEASE-FOCUSED METHYLATION RESEARCH TO AUGMENT GROWTH 429
18 COMPETITIVE LANDSCAPE 435
18.1 INTRODUCTION 435
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–MAY 2026 435
18.3 REVENUE ANALYSIS 437
18.4 MARKET SHARE ANALYSIS, 2025 438
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 440
18.5.1 STARS 441
18.5.2 EMERGING LEADERS 441
18.5.3 PERVASIVE PLAYERS 441
18.5.4 PARTICIPANTS 441
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 443
18.5.5.1 Company footprint 443
18.5.5.2 Region footprint 444
18.5.5.3 Product footprint 445
18.5.5.4 Service footprint 446
18.5.5.5 Method footprint 447
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 448
18.6.1 PROGRESSIVE COMPANIES 448
18.6.2 RESPONSIVE COMPANIES 448
18.6.3 DYNAMIC COMPANIES 448
18.6.4 STARTING BLOCKS 448
18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 450
18.6.5.1 Detailed list of key startups/SMEs 450
18.6.5.2 Competitive benchmarking of key startups/SMEs 451
18.7 COMPANY VALUATION AND FINANCIAL METRICS 452
18.7.1 COMPANY VALUATION 452
18.7.2 FINANCIAL METRICS 452
18.8 BRAND COMPARISON 453
18.9 COMPETITIVE SCENARIO 454
18.9.1 PRODUCT/SERVICE LAUNCHES 454
18.9.2 DEALS 455
19 COMPANY PROFILES 456
19.1 KEY PLAYERS 456
19.1.1 THERMO FISHER SCIENTIFIC INC. 456
19.1.1.1 Business overview 456
19.1.1.2 Products/services offered 457
19.1.1.3 Recent developments 460
19.1.1.3.1 Product launches 460
19.1.1.3.2 Deals 460
19.1.1.4 MnM view 461
19.1.1.4.1 Key strengths 461
19.1.1.4.2 Strategic choices 461
19.1.1.4.3 Weaknesses and competitive threats 461
19.1.2 ILLUMINA, INC. 462
19.1.2.1 Business overview 462
19.1.2.2 Products/Services offered 464
19.1.2.3 Recent developments 466
19.1.2.3.1 Product launches 466
19.1.2.3.2 Deals 467
19.1.2.4 MnM view 467
19.1.2.4.1 Key strengths 467
19.1.2.4.2 Strategic choices 467
19.1.2.4.3 Weaknesses and competitive threats 467
19.1.3 MERCK KGAA 468
19.1.3.1 Business overview 468
19.1.3.2 Products/Services offered 469
19.1.3.3 MnM view 471
19.1.3.3.1 Key strengths 471
19.1.3.3.2 Strategic choices 471
19.1.3.3.3 Weaknesses and competitive threats 471
19.1.4 DANAHER CORPORATION 472
19.1.4.1 Business overview 472
19.1.4.2 Products/Services offered 473
19.1.4.3 Recent developments 475
19.1.4.3.1 Deals 475
19.1.4.4 MnM view 475
19.1.4.4.1 Key strengths 475
19.1.4.4.2 Strategic choices 475
19.1.4.4.3 Weaknesses and competitive threats 475
 
19.1.5 BIO-RAD LABORATORIES, INC. 476
19.1.5.1 Business overview 476
19.1.5.2 Products/Services offered 477
19.1.5.3 MnM view 481
19.1.5.3.1 Key strengths 481
19.1.5.3.2 Strategic choices 481
19.1.5.3.3 Weaknesses and competitive threats 481
19.1.6 REVVITY 482
19.1.6.1 Business overview 482
19.1.6.2 Products/Services offered 483
19.1.7 PACBIO 485
19.1.7.1 Business overview 485
19.1.7.2 Products/Services offered 486
19.1.7.3 Recent developments 487
19.1.7.3.1 Product launches 487
19.1.7.3.2 Deals 488
19.1.8 ACTIVE MOTIF, INC. 489
19.1.8.1 Business overview 489
19.1.8.2 Products/Services offered 489
19.1.8.3 Recent developments 492
19.1.8.3.1 Deals 492
19.1.9 NEW ENGLAND BIOLABS 493
19.1.9.1 Business overview 493
19.1.9.2 Products/Services offered 493
19.1.9.3 Recent developments 495
19.1.9.3.1 Product launches 495
19.1.9.3.2 Deals 496
19.1.10 QIAGEN 497
19.1.10.1 Business overview 497
19.1.10.2 Products/services offered 498
19.1.10.3 Recent developments 499
19.1.10.3.1 Product launches 499
19.1.11 ZYMO RESEARCH CORPORATION 500
19.1.11.1 Business overview 500
19.1.11.2 Products/Services offered 500
19.1.11.3 Recent developments 503
19.1.11.3.1 Product launches 503
19.1.11.3.2 Deals 503
19.1.12 HOLOGIC DIAGENODE 504
19.1.12.1 Business overview 504
19.1.12.2 Products/services offered 505
 
19.1.13 F. HOFFMANN-LA ROCHE LTD. 508
19.1.13.1 Business overview 508
19.1.13.2 Products/services offered 509
19.1.14 PROMEGA CORPORATION 511
19.1.14.1 Business overview 511
19.1.14.2 Products/services offered 511
19.1.15 EPIGENTEK GROUP INC. 513
19.1.15.1 Business overview 513
19.1.15.2 Products/Services offered 513
19.1.15.3 Recent developments 517
19.1.15.3.1 Product launches 517
19.2 OTHER PLAYERS 519
19.2.1 EPICYPHER 519
19.2.2 FIOS GENOMICS 520
19.2.3 GENOMESCAN 521
19.2.4 CREATIVE BIOGENE 522
19.2.5 BPS BIOSCIENCE, INC. 523
19.2.6 ABNOVA CORPORATION 524
19.2.7 CREATIVE DIAGNOSTICS 525
19.2.8 BIOMODAL 526
19.2.9 10X GENOMICS 527
19.2.10 NOVOGENE CO., LTD. 528
20 RESEARCH METHODOLOGY 529
20.1 RESEARCH DATA 529
20.1.1 SECONDARY DATA 530
20.1.1.1 Key data from secondary sources 530
20.1.2 PRIMARY DATA 531
20.1.2.1 Key data from primary sources 531
20.1.2.2 Key primary participants 531
20.1.2.3 Breakdown of primary interviews 532
20.1.2.4 Key industry insights 533
20.2 MARKET SIZE ESTIMATION 534
20.2.1 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025 534
20.2.2 SEGMENTAL MARKET SIZE ESTIMATION 537
20.3 MARKET GROWTH RATE PROJECTIONS 538
20.4 DATA TRIANGULATION 540
20.5 FACTOR ANALYSIS 541
20.6 RESEARCH ASSUMPTIONS 541
20.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 542
 
21 APPENDIX 544
21.1 DISCUSSION GUIDE 544
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 550
21.3 CUSTOMIZATION OPTIONS 552
21.4 RELATED REPORTS 552
21.5 AUTHOR DETAILS 553